Trial
NCT01895127
Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Brigham and Women's Hospital
Collaborators
Alexion Pharmaceuticals, Inc.
Condition
Antibody-mediated Rejection
Intervention
Eculizumab
Why stopped
Lack of efficacy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-09-21